Oxford-based OXB has been named a Champion in the ‘Cell & Gene Therapy’ category at the 2025 CDMO Leadership Awards Europe. This recognition is based on feedback from biopharmaceutical professionals. OXB’s excellence in quality, innovation, and service is highlighted, with a growing demand for its CDMO services and a diverse client portfolio. Dr. Sebastien Ribault, OXB’s Chief Business Officer, expressed gratitude for the recognition and emphasized the company’s commitment to supporting clients in delivering transformative therapies globally. OXB, a pioneer in cell and gene therapy, offers a range of viral vector technologies and has facilities in the UK, France, and the US.

Read more at GlobeNewswire: OXB honoured at 2025 CDMO Leadership Awards Europe in ‘Cell